Samskruthi Reddy Padigepati
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Samskruthi Reddy Padigepati has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
Anindita Dutta
Illumina Artificial Intelligence Laboratory, Illumina Inc, San Diego, CA, USA
2 shared publications- Brett M. Kroncke
Division of Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center
2 shared publications - Chai-Ann Ng
Mark Cowley Lidwill Research Program in Cardiac Electrophysiology, Victor Chang Cardiac Research Institute, Darlinghurst, NSW 2010, Australia
2 shared publications - Flavia M. Facio
GeneDx LLC, Gaithersburg, MD, USA
2 shared publications Hong Gao
Illumina Artificial Intelligence Laboratory, Illumina Inc, San Diego, CA, USA
2 shared publicationsJack A. Kosmicki
Illumina Artificial Intelligence Laboratory, Illumina Inc, San Diego, CA, USA
2 shared publications
Latest Publications
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (4) , e005204
Calibrated Functional Data Decrease Clinical Uncertainty for KCNH2 -Related Long-QT Syndrome
- 1 August 2025
- Published by Wolters Kluwer Health in Circulation: Genomic and Precision Medicine
- Vol. 18 (4) , e005204
Calibrated Functional Data Decrease Clinical Uncertainty for KCNH2 -Related Long-QT Syndrome
- Open Access
Calibrated Functional Data Decreases Clinical Uncertainty for KCNH2 -related Long QT Syndrome
Rare missense variants are often classified as variants of uncertain significance (VUS) due to insufficient evidence for classification. These ambiguous findings create anxiety and frequently lead to inappropriate workup, colloquially referred to as the ‘diagnostic odyssey’. Well-validated high-throughput experimental data have the potential to significantly reduce the number of VUS identified by clinical genetic testing, though the extent of this reduction and the optimal strategies to achieve it remain unclear. 1
Open AccessCalibrated Functional Data Decreases Clinical Uncertainty for KCNH2 -related Long QT Syndrome
Rare missense variants are often classified as variants of uncertain significance (VUS) due to insufficient evidence for classification. These ambiguous findings create anxiety and frequently lead to inappropriate workup, colloquially referred to as the ‘diagnostic odyssey’. Well-validated high-throughput experimental data have the potential to significantly reduce the number of VUS identified by clinical genetic testing, though the extent of this reduction and the optimal strategies to achieve it remain unclear. 1
- 17 December 2018
- Published by Springer Nature in Nature Genetics
- Vol. 51 (2) , 364
Author Correction: Predicting the clinical impact of human mutation with deep neural networks
In the version of this article originally published, the name of author Serafim Batzoglou was misspelled. The error has been corrected in the HTML and PDF versions of the article.
- 17 December 2018
- Published by Springer Nature in Nature Genetics
- Vol. 51 (2) , 364
Author Correction: Predicting the clinical impact of human mutation with deep neural networks
In the version of this article originally published, the name of author Serafim Batzoglou was misspelled. The error has been corrected in the HTML and PDF versions of the article.
- 23 July 2018
- Published by Springer Nature in Nature Genetics
- Vol. 50 (8) , 1161-1170
Predicting the clinical impact of human mutation with deep neural networks
Millions of human genomes and exomes have been sequenced, but their clinical applications remain limited due to the difficulty of distinguishing disease-causing mutations from benign genetic variation. Here we demonstrate that common missense variants in other primate species are largely clinically benign in human, enabling pathogenic mutations to be systematically identified by the process of elimination. Using hundreds of thousands of common variants from population sequencing of six non-human primate species, we train a deep neural network that identifies pathogenic mutations in rare disease patients with 88% accuracy and enables the discovery of 14 new candidate genes in intellectual disability at genome-wide significance. Cataloging common variation from additional primate species would improve interpretation for millions of variants of uncertain significance, further advancing the clinical utility of human genome sequencing.
- 23 July 2018
- Published by Springer Nature in Nature Genetics
- Vol. 50 (8) , 1161-1170
Predicting the clinical impact of human mutation with deep neural networks
Millions of human genomes and exomes have been sequenced, but their clinical applications remain limited due to the difficulty of distinguishing disease-causing mutations from benign genetic variation. Here we demonstrate that common missense variants in other primate species are largely clinically benign in human, enabling pathogenic mutations to be systematically identified by the process of elimination. Using hundreds of thousands of common variants from population sequencing of six non-human primate species, we train a deep neural network that identifies pathogenic mutations in rare disease patients with 88% accuracy and enables the discovery of 14 new candidate genes in intellectual disability at genome-wide significance. Cataloging common variation from additional primate species would improve interpretation for millions of variants of uncertain significance, further advancing the clinical utility of human genome sequencing.